title: Pharmacokinetics and pharmacodynamics of some oximes and associated therapeutic consequences: a critical review.
abstract: Undoubtedly, the use of oximes represents real progress in counteracting intoxications with organophosphates (OP), through potentiating antidotal effects of atropine. The penetration extent of these compounds through the blood-brain barrier (BBB) to significantly reactivate phosphorylated or phosphonylated acetylcholinesterase (AChE) in the brain still remains a debatable issue. Penetration of biological barriers by oximes was investigated mainly through determination of several quantitative parameters characterizing digestive absorption and BBB penetration. A weak penetration of biological barriers could be concluded from the available experimental data. The functional parameters/therapeutic effects following the penetration of oximes through BBB, more precisely the antagonism of OP-induced seizures and hypothermia, prevention of brain damage and respiratory center protection, leading to the final end-point, the survival of intoxicated organisms, are of high interest. It seems obvious that oximes are weakly penetrating the BBB, with minimal brain AChE reactivation (<5%) in important functional areas, such as the ponto-medullar. The cerebral protection achieved through administration of oximes is only partial, without major impact on the antagonism of OP-induced seizures, hypothermia and respiratory center inhibition. The antidotal effects probably result from synergic effects of other PD properties, different from the brain AChE reactivation process. Oxime structures especially designed for enhanced BBB penetration, through potentiating the hydrophobic characteristics, more often produce neurotoxic effects. Certainly, obtaining oximes with broad action spectrum (active against all OP types) would make a sense, but certainly, such a target is not achievable only through the increase in their penetrability in the brain.
authors.affiliation: University of Medicine and Pharmacy Carol Davila, Clinical Pharmacology, Toxicology and Psychopharmacology, Bucharest, Romania. victor.voicu@yahoo.com
authors.forename: Victor A
authors.initials: VA
authors.lastname: Voicu
authors.forename: Jiri
authors.initials: J
authors.lastname: Bajgar
authors.forename: Andrei
authors.initials: A
authors.lastname: Medvedovici
authors.forename: Flavian Stefan
authors.initials: FS
authors.lastname: Radulescu
authors.forename: Dalia Simona
authors.initials: DS
authors.lastname: Miron
mesh_terms: D000110:Acetylcholinesterase / Q000378:metabolism; D000931:Antidotes / Q000494:pharmacology / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001921:Brain / Q000378:metabolism; D002801:Cholinesterase Reactivators / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007035:Hypothermia / Q000139:chemically induced; D009943:Organophosphorus Compounds / Q000633:toxicity*; D010091:Oximes / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012640:Seizures / Q000139:chemically induced; D014018:Tissue Distribution
chemical_list: D000931:Antidotes; D002801:Cholinesterase Reactivators; D009943:Organophosphorus Compounds; D010091:Oximes; C022372:phosphonylated acetylcholinesterase; D000110:Acetylcholinesterase